



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Biguanide therapy for diabetes and cancer & a novel methyltransferase that regulates energy expenditure and adiposity and is elevated in many cancers

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Kahn, Barbara B, Daniel Kraus, and Qin Yang. 2014. "Biguanide therapy for diabetes and cancer & a novel methyltransferase that regulates energy expenditure and adiposity and is elevated in many cancers." <i>Cancer & Metabolism</i> 2 (Suppl 1): O25. doi:10.1186/2049-3002-2-S1-O25. http://dx.doi.org/10.1186/2049-3002-2-S1-O25 .
Published Version	doi:10.1186/2049-3002-2-S1-O25
Accessed	February 16, 2015 4:45:08 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717592
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

ORAL PRESENTATION

Open Access

Biguanide therapy for diabetes and cancer & a novel methyltransferase that regulates energy expenditure and adiposity and is elevated in many cancers

Barbara B Kahn*, Daniel Kraus, Qin Yang

From Metabolism, Diet and Disease 2014: Cancer and metabolism
Washington DC, USA. 28-30 May 2014

Compounds containing guanidine-related molecules have been used since medieval times to relieve symptoms of diabetes mellitus. Guanidine itself was too toxic but two linked guanidine rings (biguanides) were useful and generally safer. For 20 years, phenformin was used before adverse effects led to removal from the US and European markets. Metformin continues to be widely prescribed for diabetes treatment and is associated with improved survival compared to other diabetes drugs. With the current interest in using the more potent phenformin for cancer therapy, it is timely to review the risks, benefits, and potential contraindications.

The adipose cell is as an endocrine organ in addition to its role in energy storage. Adipocytes secrete hormones, cytokines and other factors that influence energy balance, glucose homeostasis, insulin sensitivity and vascular biology. In humans with obesity and type 2 diabetes, expression of the Glut4 glucose transporter is down-regulated selectively in adipocytes resulting in systemic insulin resistance. Knocking out Glut4 selectively in adipocytes in mice increases the risk of diabetes while adipose-specific Glut4 overexpression confers enhanced glucose tolerance in spite of increased adiposity. To understand how adipocytes regulate glucose homeostasis and insulin sensitivity, we performed DNA microarray analysis of adipose tissue from mice with adipose-specific knockdown or overexpression of Glut4. The most highly reciprocally regulated gene is nicotinamide N-methyltransferase (*Nnmt*). NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. Nicotinamide is a precursor for

NAD⁺, an important cofactor linking cellular redox states with energy metabolism. NNMT expression is increased in adipose tissue and liver of obese and diabetic mice. Furthermore, NNMT knockdown in adipose tissue and liver using anti-sense oligonucleotides in mice on a high fat diet, protects against diet-induced obesity by augmenting cellular energy expenditure. This involves a novel mechanism which could provide new strategies for prevention and treatment of obesity and type 2 diabetes. Since NNMT is also elevated in many cancers, NNMT knockdown could be beneficial for cancer prevention and/or treatment.

Published: 28 May 2014

doi:10.1186/2049-3002-2-S1-O25

Cite this article as: Kahn et al.: Biguanide therapy for diabetes and cancer & a novel methyltransferase that regulates energy expenditure and adiposity and is elevated in many cancers. *Cancer & Metabolism* 2014 **2** (Suppl 1):O25.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA



© 2014 Kahn et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.